131 related articles for article (PubMed ID: 3055414)
21. Interaction between plasminogen activator inhibitor type 1 (PAI-1) bound to fibrin and either tissue-type plasminogen activator (t-PA) or urokinase-type plasminogen activator (u-PA). Binding of t-PA/PAI-1 complexes to fibrin mediated by both the finger and the kringle-2 domain of t-PA.
Wagner OF; de Vries C; Hohmann C; Veerman H; Pannekoek H
J Clin Invest; 1989 Aug; 84(2):647-55. PubMed ID: 2503541
[TBL] [Abstract][Full Text] [Related]
22. Degradation of fibrin and elastin by intact human alveolar macrophages in vitro. Characterization of a plasminogen activator and its role in matrix degradation.
Chapman HA; Stone OL; Vavrin Z
J Clin Invest; 1984 Mar; 73(3):806-15. PubMed ID: 6368589
[TBL] [Abstract][Full Text] [Related]
23. A transitional state of pro-urokinase that has a higher catalytic efficiency against glu-plasminogen than urokinase.
Liu JN; Pannell R; Gurewich V
J Biol Chem; 1992 Aug; 267(22):15289-92. PubMed ID: 1639775
[TBL] [Abstract][Full Text] [Related]
24. Biochemical properties of conjugates of urokinase-type plasminogen activator with a monoclonal antibody specific for cross-linked fibrin.
Dewerchin M; Lijnen HR; Van Hoef B; De Cock F; Collen D
Eur J Biochem; 1989 Oct; 185(1):141-9. PubMed ID: 2530085
[TBL] [Abstract][Full Text] [Related]
25. Formation of stable complexes between urokinase and a human urinary component.
Cieplak W; Hart DA
Thromb Haemost; 1985 Feb; 53(1):36-41. PubMed ID: 4039474
[TBL] [Abstract][Full Text] [Related]
26. Urokinase-related proteins in human urine. Isolation and characterization of single-chain urokinase (pro-urokinase) and urokinase-inhibitor complex.
Stump DC; Thienpont M; Collen D
J Biol Chem; 1986 Jan; 261(3):1267-73. PubMed ID: 3080422
[TBL] [Abstract][Full Text] [Related]
27. Fibrin binding and zymogenic properties of single-chain urokinase (pro-urokinase).
Gurewich V; Pannell R
Semin Thromb Hemost; 1987 Apr; 13(2):146-51. PubMed ID: 3114882
[No Abstract] [Full Text] [Related]
28. Effect of fibrin-targeting on clot lysis with urokinase-type plasminogen activator.
Lijnen HR; Dewerchin M; De Cock F; Collen D
Thromb Res; 1990 Feb; 57(3):333-42. PubMed ID: 2107593
[TBL] [Abstract][Full Text] [Related]
29. Purification and properties of a plasminogen activator from cultured rat prostate adenocarcinoma cells.
Strickland DK; de Serrano VS; Chan SY; Pollard M; Castellino FJ
Biochemistry; 1983 Sep; 22(19):4444-9. PubMed ID: 6684952
[TBL] [Abstract][Full Text] [Related]
30. Characterization of plasminogen activator from two human renal carcinoma cell lines.
Nelson NF; Cieplak W; Dacus SC; Prager MD
J Cell Physiol; 1986 Mar; 126(3):435-43. PubMed ID: 2419348
[TBL] [Abstract][Full Text] [Related]
31. Sequence of formation of molecular forms of plasminogen and plasmin-inhibitor complexes in plasma activated by urokinase or tissue-type plasminogen activator.
Thorsen S; Müllertz S; Suenson E; Kok P
Biochem J; 1984 Oct; 223(1):179-87. PubMed ID: 6208894
[TBL] [Abstract][Full Text] [Related]
32. The resistance of fibrinogen and soluble fibrin monomer in blood to degradation by a potent plasminogen activator derived from cadaver limbs.
Gurewich V; Hyde E; Lipinski B
Blood; 1975 Oct; 46(4):555-65. PubMed ID: 126095
[TBL] [Abstract][Full Text] [Related]
33. Interfering factors in the assay of plasminogen activators by the fibrin plate method. Occurrence of different inhibitors against tissue plasminogen activator and urokinase.
Wijngaards G
Thromb Haemost; 1979 May; 41(3):590-600. PubMed ID: 111368
[TBL] [Abstract][Full Text] [Related]
34. Proteolytic cleavage of single-chain pro-urokinase induces conformational change which follows activation of the zymogen and reduction of its high affinity for fibrin.
Kasai S; Arimura H; Nishida M; Suyama T
J Biol Chem; 1985 Oct; 260(22):12377-81. PubMed ID: 3930494
[TBL] [Abstract][Full Text] [Related]
35. Initial plasmin-degradation of fibrin as the basis of a positive feed-back mechanism in fibrinolysis.
Suenson E; Lützen O; Thorsen S
Eur J Biochem; 1984 May; 140(3):513-22. PubMed ID: 6233145
[TBL] [Abstract][Full Text] [Related]
36. Plasminogen activator content of human tumor and adjacent normal tissue measured with fibrin and non-fibrin assays.
Camiolo SM; Greco WR
Cancer Res; 1986 Apr; 46(4 Pt 1):1788-94. PubMed ID: 3081257
[TBL] [Abstract][Full Text] [Related]
37. Lipoprotein(a): a kinetic study of its influence on fibrin-dependent plasminogen activation by prourokinase or tissue plasminogen activator.
Liu JN; Harpel PC; Pannell R; Gurewich V
Biochemistry; 1993 Sep; 32(37):9694-700. PubMed ID: 8373773
[TBL] [Abstract][Full Text] [Related]
38. Substrate specificity of tissue plasminogen activator and urokinase as determined with synthetic chromogenic substrates.
Matsuo O; Sakai T; Takakura Y; Mihara H
Jpn J Physiol; 1983; 33(6):1031-7. PubMed ID: 6687071
[TBL] [Abstract][Full Text] [Related]
39. A plasminogen activator inhibitor-2 from a promyelocytic leukemia cell line, PL-21, binds to the carboxy-terminal chain of plasminogen activators.
Takeuchi T; Niiya K; Kubonishi I; Miyoshi I
Thromb Haemost; 1990 Apr; 63(2):259-64. PubMed ID: 2363126
[TBL] [Abstract][Full Text] [Related]
40. Hybrid molecules: insights into plasminogen activator function.
Runge MS; Bode C; Haber E; Quertermous T
Mol Biol Med; 1991 Apr; 8(2):245-55. PubMed ID: 1806766
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
